BSEKobo Biotech Ltd-$CriticalPositive
Announced Mon, 11 May · 19:33 IST

Approval of Resolution Plan and receipt of Order from NCLT

Nclt Resolution ApprovedRegulatory & Legal View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
1-day move
₹2.58
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+4.7+9.7+20.5+76.0+145.7+259.3
Up moveDown movePending
AI summary

The Hon'ble NCLT Hyderabad Bench-I has approved the Resolution Plan submitted by Beaufond Industries Limited for Kobo Biotech Limited under Section 31 of the Insolvency and Bankruptcy Code, 2016. The CIRP was initiated on August 13, 2024, and the plan was approved by the Committee of Creditors with 100% voting share on March 17, 2026. The plan provides for acquisition as a going concern with a composite restructuring including capital reduction, fresh equity issuance to the SRA, and a scheme of amalgamation/demerger. The total plan value is approximately Rs. 70.11 Crores against admitted claims of Rs. 353.59 Crores, representing an 80.82% haircut for creditors. The company will be renamed 'Beaufond Limited' and listing status will be maintained with minimum 2% public shareholding. Implementation must be completed within 60 days from NCLT approval date.

Likely market impact

Existing shareholders face complete cancellation of their share capital with no payment. Creditors will receive only 19.18% of their admitted claims. The stock may experience significant volatility as the restructuring involves capital reduction, fresh equity issuance to the new promoter, and potential changes in company identity.